RANK and RANK ligand expression in primary human osteosarcoma [PDF]
Journal of Bone Oncology, 2015 Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using ...
Daniel Branstetter +7 more
doaj +4 more sources
RANK-Ligand inhibitor associated osteonecrosis of the jaw [PDF]
GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2013 Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis.
Rashad, Ashkan +2 more
doaj +5 more sources
Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment [PDF]
Endocrinology and Metabolism, 2021 Background Dickkopf-1 (DKK1) regulates bone formation by inhibiting canonical Wnt/β-catenin pathway signaling, and indirectly enhances osteoclastic activity by altering the expression ratio of receptor activator of nuclear factor-κB ligand (RANKL ...
Eunhee Jang +3 more
doaj +2 more sources
Breast Cancer: Rank Ligand Inhibition [PDF]
Breast Care, 2010 Breast cancer and bone health are closely linked. Early menopause induced by gonadotropin-releasing hormone analogues or chemotherapy as well as aromatase inhibitors reduce oestrogen levels, thereby causing cancer treatment-induced bone loss (CTIBL). Furthermore, bone metastases are commonly found in advanced disease. Current treatment options for bone
Rupert, Bartsch +3 more
openaire +3 more sources
Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA). Methods Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab.
Mie Jin Lim +3 more
doaj +1 more source
Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2023 Osteogenesis imperfecta (OI) is an inherited skeletal disorder that leads to bone fragility and multiple fractures. Given advances in the genetic understanding of existing phenotypes and newly discovered mutations, therapeutic management of OI has become
Fatma Majdoub +5 more
doaj +1 more source
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature [PDF]
Endocrinology and Metabolism, 2022 Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption.
Wei Lin Tay, Donovan Tay
doaj +1 more source
Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).
Kyoung-Woon Kim +6 more
doaj +1 more source
N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims This study aimed to determine the regulatory role of N-acetyl-l-cysteine (NAC), an antioxidant, in interleukin 17 (IL-17)-induced osteoclast differentiation in rheumatoid arthritis (RA).
Hae-Rim Kim +4 more
doaj +1 more source
RANK and RANK Ligand Expression in Parotid Gland Carcinomas [PDF]
Applied Immunohistochemistry & Molecular Morphology, 2018 Recently, it has been reported that deregulation of the receptor activator of NFkB ligand (RANKL)/RANK signaling axis results in salivary gland tumor development in a mouse transgenic model. The aim of this study was to ascertain RANKL and RANK protein expression in a series of primary parotid gland carcinomas and to correlate it with clinicopathologic
Franchi A +6 more
openaire +4 more sources